Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $60,800.00 in Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Rosty Raykov sold 10,000 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $6.08, for a total value of $60,800.00. Following the transaction, the director now directly owns 83,863 shares of the company’s stock, valued at $509,887.04. This represents a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Rosty Raykov also recently made the following trade(s):

• On Thursday, December 5th, Rosty Raykov sold 796 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $6.04, for a total value of $4,807.84.
• On Monday, November 4th, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $4.31, for a total transaction of $10,477.61.

Fennec Pharmaceuticals Stock Performance

Shares of Fennec Pharmaceuticals stock traded up $0.02 during trading on Tuesday, hitting $6.10. 61,823 shares of the stock were exchanged, compared to its average volume of 90,081. Fennec Pharmaceuticals Inc has a 1-year low of $3.96 and a 1-year high of $11.49. The stock has a market capitalization of $167.57 million, a price-to-earnings ratio of -60.99 and a beta of 0.34. The company has a fifty day moving average price of $5.51 and a 200-day moving average price of $5.52. The company has a current ratio of 7.80, a quick ratio of 7.64 and a debt-to-equity ratio of 9.86.

Wall Street Analysts Forecast Growth

FENC has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Tuesday, December 17th. Wedbush reiterated an “outperform” rating and set a $13.00 target price on shares of Fennec Pharmaceuticals in a report on Friday, December 20th. Finally, Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.

Institutional Trading of Fennec Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Franklin Resources Inc. boosted its stake in shares of Fennec Pharmaceuticals by 18.7% during the 3rd quarter. Franklin Resources Inc. now owns 14,799 shares of the company’s stock worth $74,000 after acquiring an additional 2,330 shares during the period. Barclays PLC boosted its position in Fennec Pharmaceuticals by 274.3% during the third quarter. Barclays PLC now owns 31,319 shares of the company’s stock worth $157,000 after purchasing an additional 22,951 shares during the period. State Street Corp increased its holdings in shares of Fennec Pharmaceuticals by 2.2% in the third quarter. State Street Corp now owns 328,259 shares of the company’s stock valued at $1,641,000 after purchasing an additional 7,053 shares during the last quarter. Advantage Alpha Capital Partners LP bought a new position in shares of Fennec Pharmaceuticals in the third quarter valued at about $264,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Fennec Pharmaceuticals during the 2nd quarter worth about $69,000. Institutional investors own 55.51% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.